Revance Therapeutics Inc’s lead asset is a new form of botulinum toxin, akin to the best-selling wrinkle eraser, Botox, but with a key difference, durability, according to Chief Executive Officer Daniel Browne.

Recent results in a late-stage study may back up his claim. The Newark, California-based drug developer plans to leverage that durability claim to expand into previously untapped markets rather than just challenging Botox and its maker, Allergan Plc, Browne said in an interview at Bloomberg LP’s New York office.

When pressed on how his company could drive expansion in a field where Botox has been dominant for nearly three decades, Browne talks about moving into new therapeutic areas that Allergan hasn’t dipped into yet.